The 16th World ADC London, set to convene at ExCeL London from February 23–26, 2026, stands as Europe’s premier conference dedicated to Antibody-Drug Conjugates (ADCs). The central focus of the 2026 event is differentiation across the ADC value chain – from design to production – in response to the dominance of Topo1 and MMAE payloads and the rising threat of resistance.

The summit will host over 800 senior European ADC decision-makers, including biopharma executives, clinicians, investors, and regulators. The comprehensive agenda features five streams covering the entire lifecycle of ADCs, specifically highlighting novel cytotoxic and non-cytotoxic payloads, dual/bispecific ADCs, non-antibody conjugates, and strategies for advancing these targeted therapies into earlier-line oncology treatments for maximum patient impact.

The 16th World ADC London event is expected to feature 800+ ADC Industry Attendees representing 240+ Companies in the Room, with presentations delivered by a 120+ Global Speaker Faculty. The agenda includes 14+ Hours of Networking, offering comprehensive One-on-One Partnering and informal networking opportunities, spread across 4 Days of ADC Insights. The content is organized into 5 Tracks of End-to-End ADC Content.

View the 2026 agenda here.

Registration link.

Full Event Guide link.

You can find more posts on ADCs on OncoDaily.